TaiMed Biologics press release
TAIPEI, Taiwan, Nov. 10, 2026 — TaiMed Biologics Inc. (TPEX: 4147), a commercial-stage CD4-targeted biologics company advancing antibody-based therapies for long-acting HIV treatment, today announced the publication in The Lancet HIV of results from a Phase 1b/2a clinical study evaluating TMB-365 in combination with TMB-380 as a long-acting maintenance regimen in people living with HIV who were virologically suppressed on oral antiretroviral therapy (ART). These same findings were also delivered in an oral presentation at this year’s HIV Glasgow meeting held in Glasgow, Scotland, and the scientific article publication is available electronically on The Lancet HIV’s website.
TMB-365 is a long-acting, CD4-directed monoclonal antibody targeting a host receptor required for HIV entry, while TMB-380 is a long-acting broadly neutralizing antibody targeting the CD4-binding site of HIV-1 gp120. The publication, titled “Safety, pharmacokinetics, and antiviral activity of a combination of TMB-365 and TMB-380 in people living with HIV suppressed with antiretroviral therapy in the USA: a phase 1b/2a, open-label, dose-escalation study,” reports safety, pharmacokinetic and antiviral activity results supporting continued clinical development of the dual-antibody regimen.
Read the full press release here.
Source : GLOBE NEWSWIRE
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.